Aldeyra Therapeutics Inc (NAS:ALDX)
$ 4.82 -0.08 (-1.63%) Market Cap: 287.03 Mil Enterprise Value: 194.66 Mil PE Ratio: 0 PB Ratio: 3.37 GF Score: 41/100

Aldeyra Therapeutics Inc ADX-629 Results Call Transcript

Dec 19, 2023 / 01:00PM GMT
Release Date Price: $3.51 (+18.58%)
Operator

Hello, and welcome to the of Thera Therapeutics announced top-line results from clinical trial of ADX629 in patients with atopic dermatitis. (Operator Instructions)

I will now turn the conference over to David Burke, Head of Investor Relations. Please go ahead.

David Burke
Aldeyra Therapeutics Inc - Investor Relations

Thank you, and good morning, everyone. Today we issued a press release announcing positive top line results from the Phase two clinical trial of ADX629 in atopic dermatitis. A copy of the press release is available on the Investor & Media section of our website, www.Aldeyra.com. The press release contains important information and should be read and considered in conjunction with the slides presented in the prepared remarks made on today's call.

With me today to discuss results are Dr. Todd Brady, President and Chief Executive Officer of Aldeyra; Dr. Matthew Zirwas, founder of the Bexley Dermatology Research Clinic and board-certified dermatologists, who served

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot